Immuneering Corp
IMRX
Company Profile
Business description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Contact
245 Main Street
Second Floor
CambridgeMA02142
USAT: +1 617 500-8080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
55
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.50 | 58.00 | -0.65% |
| CAC 40 | 8,150.42 | 58.67 | -0.71% |
| DAX 40 | 24,795.94 | 328.23 | -1.31% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,332.30 | 41.21 | -0.40% |
| HKSE | 25,410.48 | 222.73 | -0.87% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,116.71 | 1,285.42 | -1.88% |
| NZX 50 Index | 13,069.39 | 45.69 | -0.35% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,686.80 | 58.80 | -0.67% |
| SSE Composite Index | 4,072.75 | 11.22 | -0.27% |